
1. nat commun. 2017 jan 31;8:14193. doi: 10.1038/ncomms14193.

sc83288 clinical development candidate treatment severe malaria.

pegoraro s(1), duffey m(2)(3), otto td(4), wang y(2)(3), rösemann r(5),
baumgartner r(1), fehler sk(1)(2)(3), lucantoni l(6), avery vm(6), moreno-sabater
a(7)(8), mazier d(7)(9), vial hj(10), strobl s(5), sanchez cp(2)(3), lanzer
m(2)(3).

author information: 
(1)4sc ag, klopferspitz 19a, 82152 martinsried, germany.
(2)department infectious diseases, parasitology, universitätsklinikum
heidelberg, im neuenheimer feld 324, 69120 heidelberg, germany.
(3)german center infection research (dzif), partner site heidelberg, 69120
heidelberg, germany.
(4)parasite genomics, wellcome trust sanger institute, wellcome genome campus,
hinxton cb10 1sa, uk.
(5)4sc discovery gmbh, klopferspitz 19a, 82152 martinsried, germany.
(6)eskitis institute drug discovery, griffith university, young, nathan
queensland 4111, australia.
(7)sorbonne universités, upmc univ paris 06, inserm u1135, cnrs erl 8255, centre 
d'immunologie et des maladies infectieuses (cimi-paris), 91 bd de l'hôpital,
f-75013 paris, france.
(8)ap-hp, hôpital st antoine, service de parasitologie-mycologie, f-75012 paris, 
france.
(9)ap-hp, groupe hospitalier la pitié-salpêtrière, service de
parasitologie-mycologie, f-75013 paris, france.
(10)dynamique des interactions membranaires normales et pathologiques, cnrs umr
5235, université montpellier ii, cc107, place eugène bataillon, 34095
montpellier, france.

erratum in
    nat commun. 2017 apr 06;8:15273.

severe malaria life-threatening complication infection the
protozoan parasite plasmodium falciparum, requires immediate treatment.
safety efficacy concerns currently used drugs accentuate need for
new chemotherapeutic options severe malaria. describe medicinal
chemistry program starting amicarbalide led two compounds with
optimized pharmacological antiparasitic properties. sc81458 clinical 
development candidate, sc83288, fast-acting compounds cure p.
falciparum infection humanized nod/scid mouse model system. detailed
preclinical pharmacokinetic toxicological studies reveal observable
drawbacks. ultra-deep sequencing resistant parasites identifies the
sarco/endoplasmic reticulum ca2+ transporting pfatp6 putative determinant of
resistance sc81458 sc83288. features, fast parasite killing, good 
safety margin, potentially novel mode action distinct chemotype
support clinical development sc83288, intravenous application for
the treatment severe malaria.

doi: 10.1038/ncomms14193 
pmcid: pmc5290327
pmid: 28139658  [indexed medline]

conflict interest statement: authors declare competing financial
interests.

